Press Release: Sanofis Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic…
Press Release: Sanofi and Regenerons Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to…
Fagrons share buy-back program: Weekly update
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s…
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment…
Press release: Availability of the Q3 2025 Aide mmoire
Availability of the Q3 2025 Aide mémoire Paris, France – September 24,…
Bavarian Nordic Announces First Half 2025 Results
COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced…
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is…
Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly…
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal…
